Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | MLNR | O43193 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AOX1 | Q06278 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.92 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | DRD1 | P21728 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL13697563 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL15472911 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL17119502 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13105406 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13900514 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL24415240 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL14342511 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13930075 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL20833993 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL18211506 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006064299-A1 | INDUSTRIAL PROCESS OF CLARITHROMYCIN ASSOCIATED WITH CONTROLLED LEVEL OF SIDE PRODUCTS | WOCKHARDT LIMITED (IN) | 2006-06-22 | — | — | WO | claimed |
| CN-117757702-B | Lactobacillus helveticus and application thereof in controlling blood sugar | 中科微智（北京）生物科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-115315195-B | Hydroxy-and methoxy-substituted flavonoids and use thereof | 弗门尼舍有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-115315194-B | Hydroxy-and methoxy-substituted flavones and use thereof | 弗门尼舍有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117701477-B | Lactobacillus paracasei and application thereof in improving intestinal diseases | 中科微智（北京）生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118043049-A | Sotosib and EGFR antibodies for the treatment of cancers comprising KRAS G12C mutations | 安进公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023060873-A1 | RARE-EARTH-ELEMENT-DOPED CARBON QUANTUM DOT RATIO FLUORESCENT PROBE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 青岛农业大学 | 2023-04-20 | — | — | WO | disclosed |
| CN-110893193-B | Novel application of bifidobacterium lactis BL-99 | 内蒙古伊利实业集团股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-110903995-B | Probiotic edible composition and food with digestion promoting effect | 内蒙古伊利实业集团股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-110893194-B | New application of bifidobacterium lactis BL-99 in inhibiting intestinal inflammation | 内蒙古伊利实业集团股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-1419450-A | Nitrate salts of antimicrobial drugs | NICOX SA (FR) | 2003-05-21 | — | — | CN | disclosed |
| CN-1336370-A | 3-deoxy-3-carbonyl-erycin lactone B and its engineeirng strain and application | INST BIOENGINEERING ACADEMY MILITARY MEDICAL SCIENCES PLA (CN) | 2002-02-20 | — | — | CN | disclosed |
| EP-0970065-A4 | ANTIBIOTICS AND PROCESS FOR PREPARATION | TRUETT WILLIAM L (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-0970065-A1 | ANTIBIOTICS AND PROCESS FOR PREPARATION | Truett, William L. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999028308-A1 | ANTIBIOTICS AND PROCESS FOR PREPARATION | TRUETT WILLIAM L (US) | 1999-06-10 | — | — | WO | disclosed |
| WO-1997037668-A1 | USE OF MACROLIDE ANTIBIOTICS FOR NONSURGICAL FEMALE STERILIZATION AND ENDOMETRIAL ABLATION | FAMILY HEALTH INTERNATIONAL (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5662941-A | ANTIBIOTICS | BOURBON PIERRE (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5633244-A | HISTAMINE-H2 ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 1997-05-27 | — | — | US | disclosed |
| WO-1996038163-A1 | COMPOSITIONS CONTAINING AN ANTIBIOTIC AND A PEPTIDE POTENTIATING THIS ANTIBIOTIC | BIOSYNTH S.R.L. (IT) | 1996-12-05 | — | — | WO | disclosed |
| US-5118799-A | Melting, cooling grinding | PHARMACIN CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |